Side effects include:
Bleeding (e.g., ecchymoses, GI bleeding, intracranial hemorrhage). 
The most common side effect associated with drotrecogin alfa has been bleeding.
Hematologic side effects have most commonly included bleeding (25% vs 18% with placebo).  The majority of events were ecchymoses or gastrointestinal tract bleeding.  Serious bleeding has been reported in 3.5% of patients (vs 2% with placebo) and included intracranial hemorrhage, life threatening hemorrhage, and any event requiring 3 or more units of packed red blood cells per days for 2 consecutive days.
Serious bleeding events have been reported at the following sites:  Gastrointestinal, intra-abdominal, intrathoracic, retroperitoneal, intracranial, genitourinary, skin or soft tissues.